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Myosin binding protein H-like 
(MYBpHL): a promising biomarker 
to predict atrial damage
Harald Lahm1, Martina Dreßen1, Nicole Beck1, stefanie Doppler1, Marcus-André Deutsch2, 
shunsuke Matsushima1, Irina Neb1, Karl Christian König1, Konstantinos sideris1, 
stefanie Voss1, Lena eschenbach1, Nazan puluca1, Isabel Deisenhofer3, sophia Doll4, 
stefan Holdenrieder5, Matthias Mann  4,6, Rüdiger Lange1,7 & Markus Krane1,7
Myosin binding protein H-like (MYBPHL) is a protein associated with myofilament structures in atrial 
tissue. the protein exists in two isoforms that share an identical amino acid sequence except for a 
deletion of 23 amino acids in isoform 2. In this study, MYBPHL was found to be expressed preferentially 
in atrial tissue. The expression of isoform 2 was almost exclusively restricted to the atria and barely 
detectable in the ventricle, arteria mammaria interna, and skeletal muscle. After atrial damage induced 
by cryo- or radiofrequency ablation, MYBPHL was rapidly and specifically released into the peripheral 
circulation in a time-dependent manner. the plasma MYBpHL concentration remained substantially 
elevated up to 24 hours after the arrival of patients at the intensive care unit. In addition, the recorded 
MYBPHL values were strongly correlated with those of the established biomarker CK-MB. In contrast, 
an increase in MYBPHL levels was not evident in patients undergoing aortic valve replacement or 
transcatheter aortic valve implantation. In these patients, the values remained virtually constant and 
never exceeded the concentration in the plasma of healthy controls. Our findings suggest that MYBPHL 
can be used as a precise and reliable biomarker to specifically predict atrial myocardial damage.
The term clinical biomarker is used for any biological substance whose presence and detection support the deci-
sions involving subsequent medical treatment or therapy. Its detection should be rapid, easy, reproducible, and 
relatively cheap. A biomarker for myocardial damage (e.g., myocardial infarction or ablation) should be exclu-
sively expressed in the myocardium and should not be detectable in the peripheral circulation under normal 
physiological conditions. Furthermore, its rapid release into the blood at the time of injury and long-lasting 
detection are necessary for an adequate diagnostic window.
In cardiovascular research, the use of biomarkers dates back to the fifties of the last century when aspartate 
aminotransferase, lactate dehydrogenase, and creatine kinase were first introduced as markers for acute coronary 
syndrome1–3. Since then, the development of more reliable and highly sensitive biomarkers for acute myocardial 
infarction has led to the use of the cardiac troponins4–7.
In our previous work, we analyzed the proteome of sixteen different regions of the healthy human heart8. In 
this study, we defined a subset of proteins that showed a significantly higher expression in the atria compared to 
the ventricles. Myosin binding protein H-like (MYBPHL) showed the strongest tissue specificity. To date, very lit-
tle is known about the biological role of MYBPHL, potential protein-protein interactions, or its exact subcellular 
localization. Recently, Barefield and colleagues showed that MYBPHL localizes to the myofilament in atrial tissue 
1Department of cardiovascular Surgery, Division of experimental Surgery, institute insure (institute for translational 
cardiac Surgery), German Heart center Munich at the technical University of Munich, Munich, Germany. 
2Department of Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, University Hospital 
Ruhr-University Bochum, Bad Oeynhausen, Germany. 3Department of cardiovascular Disease, German Heart 
center Munich at the technical University of Munich, Munich, Germany. 4Department of Proteomics and Signal 
Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany. 5Institute of Laboratory Medicine, 
German Heart center Munich, Munich, Germany. 6Novo Nordisk Foundation Center for Protein Research, Faculty 
of Health Sciences, University of copenhagen, copenhagen, Denmark. 7DZHK (German center for cardiovascular 
Research), Partner Site Munich Heart Alliance, Munich, Germany. Harald Lahm and Martina Dreßen contributed 
equally. Correspondence and requests for materials should be addressed to H.L. (email: lahm@dhm.mhn.de)
Received: 8 March 2019
Accepted: 20 June 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:9986  | https://doi.org/10.1038/s41598-019-46123-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
and may be associated with arrhythmia and dilated cardiomyopathy9. In addition, mybphl knock-out mice have 
abnormalities in the heart conduction system and increased arrhythmia9.
Here we show that MYBPHL is tremendously over-expressed in human atrial tissue compared to the ven-
tricle or other non-cardiac tissues. In particular, the mRNA of MYBPHL isoform 2 is exclusively found in the 
atria. Furthermore, we provide evidence that an induced atrial damage by cryo- or radiofrequency ablation pro-
cedures in patients suffering from atrial fibrillation provokes a rapid, time-dependent and long-lasting release 
of MYBPHL into the plasma. In different control groups, no elevated levels of MYBPHL were detected. Thus, 
our data suggest that MYBPHL can serve as a potential new biomarker to assess cardiac injury, especially atrial 
damage.
Results
MYBPHL is selectively expressed in the atria of the human heart. We previously analyzed the pro-
teome of 16 different regions of the healthy human heart. In a comparison of the atrial and ventricular proteomes, 
we identified 1,220 proteins that were expressed significantly higher in the atria, and 409 proteins had higher 
expression in the ventricles8. To verify the differential gene expression between both locations in the human heart, 
we compared the expression of several candidate genes in left and right atrial tissue (LA and RA, respectively) 
to that in the left ventricle (LV) (Fig. 1A). We found significantly higher MYBPHL expression in both the LA 
(p = 0.032) and RA (p = 0.023) compared to the LV. In contrast, four and a half LIM domains 2 (FHL2) showed 
strong expression in the LV but was barely detected in either atrium. Furthermore, latent transforming growth fac-
tor beta binding protein 2 (LTBP2) was found at significantly higher levels in the LV (p = 0.044) whereas peptidylg-
lycine alpha-amidating monooxygenase (PAM) was expressed at significantly higher levels in the RA (p = 0.044) 
compared to the LV. No apparent differences were observed for myotilin (MYOT), versican (VCAN), or secreted 
frizzled-related protein 2 (SFRP2) between these areas of the heart.
After confirming differential gene expression in atrial and ventricular tissue, we analyzed the relative pro-
tein expression of these candidate genes in 16 different heart regions based on our previously published data8. 
MYBPHL expression was restricted to the LA, RA, and atrial septum but was virtually absent from all other 
tissues analyzed (Fig. 1B). PAM was also present in increased amounts in both atria and the atrial septum with 
low expression levels in all other cardiac regions (Fig. 1C). Of the other potential atrium-specific candidate genes, 
MYOT was limited to the left atrium and atrial septum while the expression of VCAN, LTBP2, and SFRP2 did 
not display a region-specific pattern (Supplementary Fig. S1). In contrast, FHL2 protein expression was almost 
exclusively restricted to both ventricles and the ventricular septum (Fig. 1D). Thus, our results suggest MYBPHL 
and FHL2 may be useful biomarkers for the atrial and ventricular heart regions, respectively.
Figure 1. Expression of candidate genes in different tissues of the human heart. (A) Expression of candidate 
genes in left and right atrium (n = 3 each). Values represent the fold-change of gene expression compared to left 
ventricle. (B–D) Determination of the relative protein amount indicated as label-free quantification intensity of 
MYBPHL (B), PAM (C) and FHL2 (D) in 16 different regions of the human heart. Ao: aorta, AV: aortic valve, 
RCA: right coronary artery, LA: left atrium, LCA: left coronary artery, LV: left ventricle, MV: mitral valve, PA: 
pulmonary artery, PV: pulmonary valve, Pve: pulmonary vein, RA: right atrium, RV: right ventricle, SepA: atrial 
septum, SepV: ventricular septum, TV: tricuspid valve, IVC: inferior vena cava.
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MYBPHL is expressed as two different isoforms, which have an identical amino acid sequence except for a 
deletion of 23 amino acids in isoform 2 at positions 121 through 143 (Fig. 2A). We analyzed the tissue-specific 
expression of both MYBPHL isoforms, MYBPH, MYBPC3, and FHL2 in cardiac tissue (LA and LV), arterial tissue 
(arteria mammaria interna), and skeletal muscle (Fig. 2B). MYBPHL transcripts were present in all four tissues 
but at a significantly higher level in the LA (p = 0.00045) (Fig. 2C). Using isoform-specific primers, we investi-
gated whether the MYBPHL isoforms might display tissue-specific differential expression. MYBPHL isoform 1 
transcripts were found throughout all four tissues analyzed, comparable to the results obtained for MYBPHL, and 
most abundant in the LA. In contrast, the MYBPHL isoform 2 was selectively and strongly expressed in 7 of 9 LA 
samples (Fig. 2B). Its expression level in the LA was 160- to 2,500-fold higher than in the LV, arteria mammaria 
interna, and skeletal muscle with absent or very low-level expression (Fig. 2B,C). In addition, we compared the 
expression of the paralog gene MYBPH and that of MYBPC3, which is closely related to MYBPHL. MYBPH 
transcripts were found abundantly in all skeletal muscle samples compared to cardiac muscle (LA and LV) and 
arterial tissue (Fig. 2B,C). MYBPC3 was expressed in all four tissues, but predominantly in the LV (Fig. 2B,C). 
Finally, we analyzed the expression of FHL2, which was detected in all four tissues (Fig. 2B) with the highest 
expression in the LV (Fig. 2B,C). These data were consistent with that of our initial screen (Fig. 1A,D). Our results 
demonstrated that MYBPHL and its isoforms were predominantly expressed in atria, MYBPC3 and FHL2 in the 
ventricles, and MYBPH in skeletal muscle.
MYBpHL concentration is increased in plasma after atrial myocardial injury and correlates 
with known biomarkers. Having established the specific and abundant expression of MYBPHL in atrial 
tissue, we speculated that atrial damage might be reflected in the blood of such patients. Therefore, we analyzed 
MYBPHL protein concentration in the plasma from 17 patients undergoing surgical cryo- or radiofrequency 
ablation for atrial fibrillation (Supplementary Table S1). The cryoablation was performed following a standard-
ized protocol with ablation lines only in the left and right atrium. Therefore, these patients underwent a selectively 
induced atrial cardiac injury. These provoked atrial cardiac injuries are usually accompanied by strong elevation 
of known biomarkers (e.g., creatine kinase MB (CK-MB) and troponins). CK-MB and troponin levels are robustly 
increased post-operatively but do not differentiate between atrial cardiac damage due to cryoablation or a periop-
erative myocardial infarction. Therefore, a selective and specific biomarker is highly desirable for postoperative 
monitoring and decision-making for further invasive diagnostics (e.g., cardiac catheterization).
MYBPHL plasma concentrations were measured pre-operatively, upon arrival at the intensive care unit (ICU), 
and 2, 4, 6 and 24 hours thereafter. We observed a more than 3-fold (9.66 ± 1.66 vs. 31.19 ± 8.56 ng/mL) increase 
in MYBPHL concentrations upon arrival at the ICU. Subsequently, the concentration gradually declined until 
Figure 2. MYPHL isoform 2 is specifically expressed in human atrial tissue. (A) Structure of MYBPHL 
isoforms 1 and 2.  non-coding regions,  deleted in isoform 2. Arrows indicate the location of primers 
used to amplify MYBPHL (black arrows), isoform 1 (green arrows) or isoform 2 (red arrows). (B) Gene 
expression in human LA, LV, arteria mammaria interna and skeletal muscle tissue. In each slot of the gel 20 µL 
of amplified fragments were loaded. (C) Quantification of relative gene expression in LA vs. LV, arteria 
mammaria interna and skeletal muscle tissue. Values are expressed as the mean ± SE. *p < 0.05, **p < 0.01, 
***p < 0.001.
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24 hours post-operation. The levels at this time point (15.11 ± 3.07 ng/mL) were still higher than pre-operative 
levels (Fig. 3A).
Next, we analyzed two different subgroups of ablation therapy. One group underwent endocardial cryoabla-
tion after the opening of the right and left atrium by performing a subset of at least six ablation lines, including 
box-lesions. These box-lesions created a circular isolation of both left and right pulmonary veins. Further lines 
connecting both box-lesions and additional lines were created to the left appendage and the mitral valve annu-
lus10. The endocardial cryoablation was performed in patients undergoing mitral and/or tricuspid valve sur-
gery. The second group underwent epicardial radiofrequency ablation of the pulmonary veins (Supplementary 
Table S1) concomitant with aortic valve replacement or coronary artery bypass grafting. In patients with endo-
cardial cryoablation, MYBPHL values increased more than 3-fold to approximately 35 ng/mL upon arrival at 
the ICU (Fig. 3B). In contrast, MYBPHL levels only increased to 20 ng/mL in patients with epicardial ablation 
(Fig. 3C). This difference could be due to the more aggressive and comprehensive nature of endocardial cryoab-
lation therapy compared to localized epicardial radiofrequency ablation. Thus, MYBPHL values were in good 
agreement with the degree of atrial damage. It is known that cardiac injury induced by ablation therapy also 
leads to elevated plasma levels of CK-MB and troponin T (markers of cardiac damage) released from atrial tissue 
(cardiomyocytes). In the current study, we also found significantly increased levels of both biomarkers over time 
(p < 0.001) (Supplementary Figs S2 and S3). Furthermore, the lower degree of atrial damage induced by radiofre-
quency ablation was also reflected by lower CK-MB values within this group (Supplementary Fig. S2).
Finally, we analyzed the correlation between MYBPHL and CK-MB concentrations at different time points. 
We obtained a good correlation for all MAZE patients and those who received either endocardial or epicardial 
ablation (R2 = 0.9908, 0.9882, and 0.7658, respectively) (Fig. 3D–F). In contrast, there was no correlation between 
the concentrations of MYBPHL and troponin T in these groups of patients (R2 between 0.0675 and 0.1867) 
(Supplementary Fig. S3). Thus, MYBPHL is a newly identified biomarker of cardiac damage that can rapidly 
detect cardiac necrosis upon arrival at the ICU. Furthermore, it is substantially elevated up to 24 hours after the 
procedure and correlates nicely with a known and established biomarker for cardiac damage (CK-MB).
MYBpHL concentration in plasma of patients undergoing cardiac surgery without atrial myo-
cardial injury. To judge pre-operatively measured values of patients undergoing a MAZE procedure, we 
measured the concentration of MYBPHL in the plasma of 11 healthy volunteers. There was no significant dif-
ference (p = 0.368) in the MYBPHL concentrations of these healthy volunteers and the pre-operative levels of 
patients undergoing the MAZE procedure (Fig. 4A).
To further investigate the hypothesis that MYBPHL release into circulation could be used as a specific bio-
marker for myocardial injury, we analyzed two additional groups of surgical patients. The first group underwent 
aortic valve replacement (AVR) using a conventional surgical procedure with median sternotomy and cardio-
pulmonary bypass (Supplementary Table S2). During the whole period, the plasma MYBPHL concentrations 
did not deviate significantly from the pre-operative values for this group. In addition, the values did not exceed 
the concentrations measured in healthy volunteers at any of the time points evaluated (Fig. 4B). The second 
group underwent a transcatheter aortic valve implantation (TAVI). These patients routinely present with a higher 
age and more concomitant disease (Supplementary Table S2). The TAVI procedure does not need sternotomy, 
Figure 3. MYBPHL protein in plasma is increased after atrial damage. (A) Time course of MYBPHL in patients 
with atrial fibrillation receiving cryo-ablation (n = 17). (B,C) Time course of MYBPHL expression in atrial 
fibrillation patients with endo- (B) (n = 12) or epicardial (C) (n = 5) cryo-ablation. (D–F) Correlation between 
MYBPHL and CK-MB. Values are presented as the mean ± SEM. *p < 0.05, **p < 0.01.
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cardiopulmonary bypass, or cardioplegic arrest and is, therefore, a less invasive procedure compared to AVR. We 
found that MYBPHL concentrations in this patient group also remained similar to the pre-operative concentra-
tions and never exceeded the levels in the plasma of healthy volunteers, except for a minor increase (p > 0.1) at the 
time of arrival at the ICU and two hours later (Fig. 4C). Furthermore, the MYBPHL concentrations measured in 
TAVI and AVR patients never reached the levels found in patients undergoing artificially induced atrial damage 
either by endo- or epicardial ablation (see Fig. 3).
Thus, our data strongly suggest that serum MYBPHL concentrations are only elevated in the case of myo-
cardial damage. Furthermore, serum MYBPHL levels are similar between healthy volunteers and pre-operative 
values from patients suffering from cardiovascular disease.
MYBPHL concentration in patients with atrioventricular node ablation. Recently, Barefield et al. 
described – beside the atrial expression – specific expression of MYBPHL in the cells of the conduction system of 
the heart9. Therefore, we aimed to quantify the release of MYBPHL in patient plasma after atrioventricular node 
(AVN) ablation (Supplementary Table S3). To this end, samples from a different study using a slightly differing 
protocol for blood sample withdrawal (Supplementary Fig. S4A) were analyzed for the plasma MYBPHL concen-
tration. Pre-operative MYBPHL levels were higher in patients undergoing AVN ablation compared to all other 
groups, but the differences did not reach significance (p > 0.081). Furthermore, no significant differences in the 
plasma MYBPHL concentrations were observed between the pre- and post-procedural time points (up to 24 h 
post-procedure) (Supplementary Fig. S4B).
Discussion
In our present work, we identified MYBPHL as a gene that is preferentially and most abundantly (up to 300-fold) 
expressed in human atria compared to the ventricles, arteria mammaria interna, or skeletal muscle. These results 
are similar to those of comparative microarray analyses11,12. In addition, these results are consistent with our pre-
vious work, which demonstrated that MYBPHL protein was strongly enriched in the atrial tissue of the human 
heart8. Additional examination of the distribution of MYBPHL protein in 16 cardiac tissues confirmed that it was 
absent or barely detectable in all but atrial tissue in the heart. Though MYBPHL is processed into two isoforms, 
Figure 4. MYBPHL is not increased in plasma of patients without atrial damage. (A) Comparison of MYBPHL 
concentration in plasma of healthy volunteers (n = 11) with pre-OP values of patients with myocardial injury 
(n = 17). (B,C) Time course of MYBPHL in patients with AVR (B) (n = 5) or TAVI (C) (n = 5). The red line 
represents the mean concentration of MYBPHL in plasma of healthy controls. Values are presented as the 
mean ± SEM. n.s.: not significant.
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their tissue specificity had not been previously evaluated. We detected isoform 1 transcripts in all four tissues 
examined. However, it was expressed predominantly in the left atrial tissue. With the exception of atrial tissue, 
isoform 2 transcripts were only detectable at negligible levels in a few samples. The closely related MYBPC3 gene, 
which shares a fibronectin-3 and an immunoglobulin C-2 type domain at the C terminus with MYBPHL, was 
predominantly expressed in ventricular tissue while MYBPH, a paralog of MYBPHL, appeared to be a marker of 
skeletal muscle. Therefore, MYBPHL and, in particular, isoform 2 appeared to be expressed very selectively in the 
atria of the human heart, suggesting its potential use as an atrium-specific biomarker.
Currently, there are no existing biomarkers that can be used to specifically monitor damage to atrial tissue. 
Different cardiac-specific biomarkers (e.g., CK-MB, troponin T, and troponin I) have been evaluated follow-
ing surgical- or catheter-based ablation procedures. All of these markers are significantly increased after abla-
tion13,14. However, none of these have significant prognostic value, most probably due to their lack of specificity 
for the atrial myocardium. Nevertheless, monitoring the extent of atrial damage could be of paramount interest, 
especially after surgical- or catheter-based ablation procedures. A potential marker could indicate the short- or 
long-term success of a procedure by reflecting the specific degree of ablated atrial myocardium. Furthermore, 
an atrium-specific biomarker could be a valuable tool to differentiate between atrial and ventricular damage. 
Iatrogenic ventricular damage could occur, for example, during concomitant surgical procedures, such as mitral 
valve surgery by occlusion of a coronary vessel. Our results clearly show that MYBPHL can serve as a marker to 
detect such an injury. After cryo- or radiofrequency ablation, the concentration of MYBPHL in the plasma of 
these patients increased substantially after the operation and then gradually declined to almost pre-operative val-
ues 24 hours after the procedure. After the more intensive endocardial ablation, MYBPHL increased to higher val-
ues compared to the less extensive epicardial therapy. These results were in good agreement with the hypothesis 
that more severe damage in the atrium would induce a greater release of MYBPHL into the peripheral circulation.
To evaluate cardiac injury, highly sensitive assays have been established that measure the release of cardiac 
troponin T and I, especially upon acute myocardial infarction7,15. However, the increase in troponin can also 
be the result of conditions other than myocardial infarction (e.g., myocarditis and non-cardiac pathology, such 
as renal failure)16,17. To confirm the specificity of MYBPHL increase after atrial damage, we included additional 
control groups in our study. Firstly, we analyzed the time-course in patients with AVR, who needed the support of 
a heart-lung machine during the operation. Secondly, we investigated TAVI patients, who underwent a minimally 
invasive intervention. In both groups, the plasma concentration of MYBPHL did not change significantly from 
pre-operative levels and never went above the concentrations in the plasma of healthy individuals. Thus, our data 
demonstrate that MYBPHL plasma concentrations increase specifically after an atrial injury. Given the fact that 
MYBPHL isoform 2 has an expression pattern that is almost exclusively restricted to the atria, it would be most 
desirable to use discriminating antibodies against this isoform to further enhance the specificity. However, such 
an antibody is not currently available.
It is most desirable to detect any potential cardiac damage as early as possible. The time to obtain a positive and 
meaningful result after cardiac damage for the troponins or CK-MB levels ranges from one to three hours7,18. Our 
data demonstrated that MYBPC3, also known as cMyBP-C, is predominantly expressed in ventricular tissue. In a 
pig model, cMyBP-C was released quite early after ligation of the left anterior descending coronary artery (LAD), 
which induced a sizeable infarction. At this early time point (30 minutes after LAD ligation), the established 
biomarkers for myocardial infarction (cardiac troponin I and T) still remained at basal levels19. This time point is 
comparable to the period between the release of cross-clamping and start of reperfusion after ablation in patients 
in whom a modified MAZE procedure has been performed and their arrival at the ICU (60–90 min). Even after 
this short period, MYBPHL concentrations in the plasma were significantly increased over the pre-operative val-
ues. MYBPHL is closely related to MYBPC3 structurally. The latter is quite susceptible to proteolysis upon cardiac 
stress20. Due to their structural relationship, this proteolytic susceptibility may also be the case for MYBPHL and 
contribute to its early release into the periphery. The concentration of MYBPHL remained markedly elevated up 
to twenty-four hours post-operation. Therefore, plasma MYBPHL appears to be a biomarker for atrial damage 
that can be measured rather early and continuously for up to twenty-four hours.
The understanding of the potential role of MYBPHL in cardiac disease is very limited. The MYBPHL gene is 
located on human chromosome 1p13.3. This locus has been identified as one of the most significant risk factors 
for coronary artery disease (CAD)21,22. In addition, the same chromosomal locus is strongly associated with the 
concentration of LDL cholesterol23,24, a causal risk factor for CAD. MYBPHL is present in the myofilament frac-
tion of the atria, which is abolished in a truncated form harboring a premature stop codon. This mutation has 
been discovered in a family where carriers suffered from cardiomyopathy and conduction system abnormalities9. 
The reported expression of MYBPHL in conduction system cells prompted us to measure MYBPHL concentra-
tion in patients undergoing selective AVN ablation. However, we were not able to show a significant increase in 
the MYBPHL concentration in the plasma over 24 hours in this patient population, which could be due to the 
low release of MYBPHL in the circulation by selective AVN ablation that causes only a small degree of damage. 
In addition, higher pre-procedural levels in this patient population may mask significantly increased levels due 
to the ablation.
In conclusion, we have identified MYBPHL as a gene that is predominantly expressed in atrial tissue, espe-
cially MYBPHL isoform 2, which is barely detectable in the ventricles or non-cardiac tissues. Upon artificially 
induced atrial damage, MYBPHL is released into the blood with peak levels reached approximately two hours 
post-operation and can easily be detected in the plasma. Interestingly, the increase in MYBPHL levels in circula-
tion is correlated with the extent of the atrial damage (endocardial versus epicardial) and matches the kinetics of 
the well-established marker CK-MB. Patients without atrial damage, regardless of whether they are connected to a 
heart-lung machine or not, never had detectable MYBPHL levels in their plasma which exceeded those measured 
in healthy individuals. Taken together, our data suggest that MYBPHL may be a useful biomarker for monitoring 
atrial damage.
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Materials and Methods
patients and biopsies. Human tissue biopsies and blood samples were obtained from the cardiovascular 
biobank (KaBi-DHM) at the German Heart Center Munich. All samples in the KaBi-DHM were obtained with 
informed consent signed by all participants or their legal guardians. All procedures and sampling were approved 
by the local ethics committee of the medical faculty at the Technical University of Munich (Project nos. 5943/13 
and 223/18S). All study procedures were performed in accordance with relevant guidelines and regulations.
Assessment of gene expression by qRt-pCR. Frozen human left and right atria, left ventricles, arteria 
mammaria interna, and skeletal muscle samples were minced in 1 mL peqGOLD TriFastTM (Peqlab, Erlangen, 
Germany) for 30 sec using an Ultraturrax MICCRA D-8 (ART Moderne Labortechnik, Müllheim, Germany). 
Total RNA was extracted according to the manufacturer’s protocol and reverse-transcribed into cDNA using 
M-MLV reverse transcriptase (150 U, Invitrogen, Carlsbad, CA), random hexamer primers (375 ng), dNTPs 
(10 mM each), 10 mM DTT, and 1× first strand buffer in a final volume of 30 µL. Amplification was performed 
using a QuantStudio 3 (ThermoFisher, Dreieich, Germany) with 5 µM of each primer and Power SYBR green 
master mix (ThermoFisher). To specifically detect the MYBPHL isoforms, we selected primers located in the 
junction site of the deletion in isoform 2 (Supplementary Table S4). The following conditions were used: 95 °C 
for 10 min to activate Taq polymerase followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Relative gene 
expression was normalized to β-ACTIN expression as a reference.
Protein expression in different heart regions. The relative amounts of proteins in different regions of 
the human heart were quantified using the label-free quantification (LFQ) method from the mass spectrometry 
data of our previous publication8.
Measurement of MYBpHL in plasma by eLIsA. Blood samples were collected in K3-EDTA tubes prior 
to the operation (Sarstedt, Nürmbrecht, Germany), upon arrival at the intensive care unit (0 h), and then 2, 4, 6, 
and 24 hours later. Samples were centrifuged for 10 min at 2,000 × g. For patients undergoing atrioventricular 
ablation, blood was drawn prior to the operation and then 6 and 24 hours post-surgery. Plasma was aliquoted 
(200 µL/aliquot) and frozen immediately at −80 °C. A commercially available ELISA kit (Cat.no. MBS9334464, 
Mybiosource.com, San Diego, CA) was used to determine the concentration of MYBPHL according to the man-
ufacturer’s instructions. In brief, all reagents were brought to room temperature and 50 µL of undiluted plasma or 
standards and 100 µL HRP-conjugate were directly pipetted into the ELISA plates and incubated for 1 h at 37 °C. 
After washing the plates four times, the chromogen solutions were added, and the plates incubated for 15 min at 
37 °C in the dark. After the addition of the stop solution, the OD at 450 nm was measured. For each assay, a stand-
ard curve was included to calculate the values for individual samples. There was a highly linear correlation up 
to concentrations of 100 ng/mL, and a lower detection limit of approximately 3 ng/mL (Supplementary Fig. S5). 
In addition, both intra- and inter-assay variation and the differences between plasma and serum are satisfying 
(Supplementary Figs S6, S7 and S8).
statistical analysis. Relative gene expression of candidate genes was calculated with the relative expression 
software tool (REST©)25 using β-ACTIN as a reference. For the expression of MYBPHL, MYBPHL isoform 1 and 2, 
MYBPH, MYBPC3, and FHL2 in tissues, standard curves were established to determine the arbitrary units of gene 
expression with β-ACTIN as a reference. The two-sided t-test was used to determine significant differences. To 
assess the significance between plasma concentrations at different time points, the one-sided t-test was applied, 
except for the difference between healthy controls and MAZE patients (Fig. 4A), where a two-sided t-test was 
used. In all cases, a p-value of <0.05 was considered to be significant.
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